Schizophrenia: Clinical Trials

53 trials for Schizophrenia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

53 terminated. 53 Phase 3, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 353Terminated 53
Phase 28Terminated 8

Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia

Trials (filtered) newest first · largest first

All 53 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Clozapine, Esketamine Nasal Product, Escitalopram - Schizophrenia and Related Disorders, Major Depressive Disorder
Phase 3TerminatedDr. Inge Winter12025-04-272026-11-05
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
Valbenazine, Placebo - Schizophrenia
Phase 3TerminatedNeurocrine Biosciences82023-01-052024-11-12
An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
Xanomeline and Trospium Chloride Capsules - Schizophrenia
Phase 3TerminatedKaruna Therapeutics, Inc., a Bristol Myers Squibb company42022-11-082024-06-12
Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia
Cariprazine, Placebo - Schizophrenia
Phase 3TerminatedAbbVie342022-08-182025-10-20
A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan
SEP-363856 - Schizophrenia
Phase 3TerminatedSumitomo Pharma Co., Ltd.682022-05-162025-03-19
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
Iclepertin - Schizophrenia
Phase 3TerminatedBoehringer Ingelheim13562022-03-212026-04-08
A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase
SEP-363856 50 mg, SEP-363856 75 mg, Placebo - Schizophrenia
Phase 2 / Phase 3TerminatedSumitomo Pharma Co., Ltd.832021-03-292024-03-15
A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia
SEP-363856 - Schizophrenia
Phase 3TerminatedOtsuka Pharmaceutical Development & Commercialization, Inc.4632019-11-202024-12-16
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
Abilify MyCite® - Schizophrenia
Phase 3TerminatedOtsuka Pharmaceutical Development & Commercialization, Inc.2772019-04-292021-09-05
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
Placebo, AVP-786 - Schizophrenia
Phase 2 / Phase 3TerminatedOtsuka Pharmaceutical Development & Commercialization, Inc.1362019-02-152026-09-29
Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia
WSE, Placebo Oral Tablet - Schizophrenia
Phase 2 / Phase 3TerminatedChengappa, K.N. Roy, MD472018-12-012024-10-08
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia
Cariprazine, Placebo - Schizophrenia
Phase 3TerminatedAbbVie5872018-07-302022-04-11
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
Lu AF35700, Risperidone, Olanzapine - Treatment-resistant Schizophrenia
Phase 3TerminatedH. Lundbeck A/S1192017-07-202020-01-21
Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults
NaBen®, Placebo - Schizophrenia
Phase 2 / Phase 3TerminatedSyneuRx International (Taiwan) Corp2802017-03-292024-05-24
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
Pimavanserin - Schizophrenia
Phase 3TerminatedACADIA Pharmaceuticals Inc.9952017-01-012025-08-24
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
N-Acetylcysteine, Placebo, IPPI (Integrated Preventive Psychological Intervention) - Prodromal Schizophrenia
Phase 3TerminatedUniversity Hospital, Bonn482016-09-012022-05-09
Pharmacovigilance in Gerontopsychiatric Patients
Phenobarbital, Phenytoin, Carbamazepine - Dementia, Depression
Phase 3TerminatedHannover Medical School4072015-01-012018-02-28
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
NaBen®, Placebo - Schizophrenia
Phase 2 / Phase 3TerminatedSyneuRx International (Taiwan) Corp602014-06-012024-05-09
SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg), Placebo - Schizophrenia
Phase 3TerminatedShire12013-02-012021-06-22
Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
SPD489 - Schizophrenia
Phase 3TerminatedShire22013-02-012021-06-22

Showing 20 of 53. Sign in to see all of them.

Narrower conditions

Psychotic Disorders (7)  ·  Bipolar Disorder (3)  ·  Cognitive Dysfunction (2)  ·  Metabolic Syndrome (2)  ·  Anxiety Disorders (1)  ·  Body Weight Changes (1)  ·  Dementia (1)  ·  Depression (1)  ·  Depressive Disorder, Major (1)  ·  Empowerment (1)  ·  Mania (1)  ·  Marijuana Abuse (1)  ·  Medication Adherence (1)  ·  Psychophysiologic Disorders (1)

Broader conditions

Mental Disorders (53)  ·  Schizophrenia Spectrum and Other Psychotic Disorders (53)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Signs and Symptoms (4)  ·  Bipolar and Related Disorders (3)  ·  Mood Disorders (3)  ·  Neurocognitive Disorders (3)  ·  Behavior (2)  ·  Body Weight (2)  ·  Cognition Disorders (2)  ·  Glucose Metabolism Disorders (2)  ·  Hyperinsulinism (2)  ·  Insulin Resistance (2)  ·  Metabolic Diseases (2)  ·  Nervous System Diseases (2)

Interventions

Quetiapine Fumarate (11)  ·  Aripiprazole (8)  ·  Risperidone (8)  ·  bifeprunox (6)  ·  ziprasidone (6)  ·  LY 2140023 (4)  ·  Olanzapine (4)  ·  Lisdexamfetamine Dimesylate (3)  ·  Memantine (3)  ·  SEP-363856 (3)  ·  Bupropion (2)  ·  Clozapine (2)  ·  Escitalopram (2)  ·  Lithium (2)  ·  Sertraline (2)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc. (7)  ·  AstraZeneca (4)  ·  Denovo Biopharma LLC (4)  ·  H. Lundbeck A/S (4)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (4)  ·  Shire (3)  ·  AbbVie (2)  ·  Hannover Medical School (2)  ·  M. Schaefer, MD (2)  ·  Sumitomo Pharma Co., Ltd. (2)  ·  SyneuRx International (Taiwan) Corp (2)  ·  Wyeth is now a wholly owned subsidiary of Pfizer (2)  ·  ACADIA Pharmaceuticals Inc. (1)  ·  Augusta University (1)  ·  BioLineRx, Ltd. (1)

Countries

United States (30)  ·  Ukraine (11)  ·  Bulgaria (9)  ·  Germany (9)  ·  Russia (9)  ·  Poland (8)  ·  Taiwan (8)  ·  Romania (7)  ·  Japan (6)  ·  Malaysia (6)  ·  Puerto Rico (6)  ·  Canada (5)  ·  Croatia (5)  ·  India (5)  ·  Serbia (5)

Top investigators

Martin Schaefer, MD (2)  ·  Anantha Shekhar, MD, PhD (1)  ·  Arnon Aharon, MD (1)  ·  Birgit Ekholm, MD (1)

Results publications

PMID 24111983, PMID 31390660, PMID 32840872, PMID 17474812, PMID 18447935, PMID 23898805, PMID 24772351, PMID 25890643, PMID 28088223, PMID 35421287, PMID 36369028, PMID 38085556, PMID 41401709

NIH funding

2005 (1), 2016 (1), 2017 (1), 2019 (1)